ArticleNature communications2021
Efficient intracellular delivery of proteins by a multifunctional chimaeric peptide in vitro and in vivo.
Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 103 citations in OpenAlex.
- Rational engineering of an antifreeze-based biomaterial with dual-enhanced ice-binding and delivery for high-efficiency cryopreservation.Journal of advanced research · 2026Article
- Biomacromolecule-MOF Composites for Intracellular Delivery: From Empirical Construction to Rational Design and AI-Assisted Screening.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
- Prospects and challenges in intracellular delivery of therapeutic proteins.Pharmacological reports : PR · 2026Review
- Targeted degradation of c-Myc through the midnolin-proteasome pathway.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Peptide-Mediated Precise Intracellular Delivery of Bioactive Substances.International journal of nanomedicine · 2026Review
- An AIEgen-Based Carrier Enables Efficient Cytosolic Delivery of Bioactive Proteins.International journal of nanomedicine · 2026Article
- Condensate nanovaccine adjuvants augment CD8Signal transduction and targeted therapy · 2025Article
- Inhibition of tumor growth using A conjugated nanobody that specifically targets c-MYC.Oncogene · 2025Article
- Injectable Endoplasmin-Loaded Lipid Nanoparticles-Hydrogel Composite for Cartilage Regeneration.Tissue engineering and regenerative medicine · 2025Article
- Advances in Cytosolic Delivery of Proteins: Approaches, Challenges, and Emerging Technologies.Chemistry & biodiversity · 2025Review
- Efficient Direct Cytosolic Protein Delivery via Protein-Linker Co-engineering.ACS applied materials & interfaces · 2025Article
- Intracellular protein editing enables incorporation of noncanonical residues in endogenous proteins.Science (New York, N.Y.) · 2025Article
- An optimized integrin α6-targeted peptide capable of delivering toxins for melanoma treatment.Journal of translational medicine · 2025Article
- Spatiotemporally resolved mapping of extracellular proteomes via in vivo-compatible TyroID.Nature communications · 2025Article
- Rewriting the script: gene therapy and genome editing for von Willebrand Disease.Frontiers in genome editing · 2025Review
- Nanocarriers for intracellular delivery of proteins in biomedical applications: strategies and recent advances.Journal of nanobiotechnology · 2024Review
- A small-molecule carrier for the intracellular delivery of a membrane-impermeable protein with retained bioactivity.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Cytosolic delivery of monobodies using the bacterial type III secretion system inhibits oncogenic BCR: ABL1 signaling.Cell communication and signaling : CCS · 2024Article
- Review
- Cell-Penetrating Peptide-Mediated Biomolecule Transportation in Artificial Lipid Vesicles and Living Cells.Molecules (Basel, Switzerland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Protein delivery with cell-penetrating peptide is opening up the possibility of using targets inside cells for therapeutic or biological applications; however, cell-penetrating peptide-mediated protein delivery commonly suffers from ineffective endosomal escape and low tolerance in serum, thereby limiting in vivo efficacy. Here, we present an intracellular protein delivery system consisting of four modules in series: cell-penetrating peptide, pH-dependent membrane active peptide, endosome-specific protease sites and a leucine zipper. This system exhibits enhanced delivery efficiency and serum tolerance, depending on proteolytic cleavage-facilitated endosomal escape and leucine zipper-based dimerisation. Intravenous injection of protein phosphatase 1B fused with this system successfully suppresses the tumour necrosis factor-α-induced systemic inflammatory response and acetaminophen-induced acute liver failure in a mouse model. We believe that the strategy of using multifunctional chimaeric peptides is valuable for the development of cell-penetrating peptide-based protein delivery systems, and facilitate the development of biological macromolecular drugs for use against intracellular targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.